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Abstract
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Proteins possessing a C-terminal CaaX motif, such as the Ras GTPases, undergo extensive posttranslational modification that includes attachment of an isoprenoid lipid, proteolytic processing
and carboxylmethylation. Inhibition of the enzymes involved in these processes is considered a
cancer-therapeutic strategy. We previously identified nine in vitro inhibitors of the yeast CaaX
protease Rce1p in a chemical library screen (Manandhar et al., 2007). Here, we demonstrate that
these agents disrupt the normal plasma membrane distribution of yeast GFP–Ras reporters in a
manner that pharmacologically phenocopies effects observed upon genetic loss of CaaX protease
function. Consistent with Rce1p being the in vivo target of the inhibitors, we observe that
compound-induced delocalization is suppressed by increasing the gene dosage of RCE1.
Moreover, we observe that Rce1p biochemical activity associated with inhibitor-treated cells is
inversely correlated with compound dose. Genetic loss of CaaX proteolysis results in mistargeting
of GFP–Ras2p to subcellular foci that are positive for the endoplasmic reticulum marker Sec63p.
Pharmacological inhibition of CaaX protease activity also delocalizes GFP–Ras2p to foci, but
these foci are not as strongly positive for Sec63p. Lastly, we demonstrate that heterologously
expressed human Rce1p can mediate proper targeting of yeast Ras and that its activity can also be
perturbed by some of the above inhibitors. Together, these results indicate that disrupting the
proteolytic modification of Ras GTPases impacts their in vivo trafficking.
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Introduction

Author Manuscript

Members of the Ras GTPase family and certain other isoprenylated proteins are synthesized
as precursors having a highly degenerate C-terminal tetrapeptide CaaX motif (C = cysteine;
a aliphatic amino acid; X = one of several amino acids). These so-called CaaX proteins
undergo an ordered series of modifications (Winter-Vann and Casey, 2005; Young et al.,
2001). The first of these modifications is the covalent attachment of an isoprenoid lipid to
the sulphhydryl side-chain of the landmark cysteine of the CaaX motif. This event is
mediated by either the farnesyltransferase (FTase; a heterodimer of Ram1p and Ram2p) or
the geranyl-geranyl transferase I (GGTase I; a heterodimer of Ram2p and Cdc43p).
Isoprenylation is followed by an endoproteolytic event that removes the last three residues of
the motif (i.e. aaX). The Ras-converting enzyme (Rce1p) and sterile mutant 24 (Ste24p) can
independently mediate this cleavage, despite being otherwise unrelated enzymes
(Boyartchuk et al., 1997; Tam et al., 1998). Rce1p and Ste24p are only partly redundant.
While both enzymes can promote production of the yeast a-factor mating pheromone, each
also has specific target substrates (Tam et al., 2001). For example, Rce1p cleaves Ras
precursors (Otto et al., 1999; Schmidt et al., 1998), while mammalian Ste24p (ZmpSte24) is
involved in maturation of mammalian lamin A (Corrigan et al., 2005; Young et al., 2006)
and is genetically implicated in yeast membrane protein topogenesis (Tipper and Harley,
2002). Completing the set of modifications is carboxyl methyl esterification of the
isoprenylated cysteine by the isoprenyl cysteine methyltransferase (ICMT; Ste14p).
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The isoprenoid transferases are cytosolic enzymes, while the CaaX proteases and ICMT are
integral membrane proteins that localize to the endoplasmic reticulum (ER) (Bracha-Drori et
al., 2008; Dai et al., 1998; Romano et al., 1998; Schmidt et al., 1998). These observations
and the fact that the Ras GTPases are predominantly plasma membrane-localized imply that
CaaX proteins must be trafficked to their final destinations (Schmidt et al., 1998). The nature
of this trafficking is largely uncharacterized for most CaaX proteins. Where this issue has
been investigated, Ras has typically been the enzyme of focus. In mammalian systems, NRas and H-Ras, but not K-Ras4B, rely on the secretory pathway for targeting to the plasma
membrane (Choy et al., 1999). However, the plasma membrane is not the only site capable
of anchoring Ras signalling platforms. In yeast, ample evidence exists for the localization of
Ras to the ER and mitochondria, but the manner by which Ras is trafficked to these
destinations has not yet been elucidated (Onken et al., 2006; Sobering et al., 2003). These
atypically localized Ras signalling platforms can elicit cellular responses distinct from that
of plasma membrane-based platforms (Philips, 2005).
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Disrupting the post-translational modification of CaaX proteins often yields intermediates
having disrupted function (Boyartchuk et al., 1997; Caplan et al., 1992b; Kato et al., 1992;
Wright and Philips, 2006). Mislocalization of CaaX protein intermediates may in part
explain observed protein dysfunction (Bergo et al., 2000; Boyartchuk et al., 1997; WinterVann et al., 2005). Because of the prominent and active role of CaaX proteins in cellular
transformation (i.e. the Ras GTPases), disrupting the post-translational modification of
CaaX proteins is perceived as an anti-cancer strategy (Winter-Vann and Casey, 2005). To
date, most drug discovery efforts have centred on FTase inhibitors (FTIs) because the FTase
is the best-characterized enzyme of those that modify CaaX proteins (Cox and Der, 2002;
Yeast. Author manuscript; available in PMC 2018 March 27.
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Zhu et al., 2003). Nonetheless, inhibitors of the CaaX proteases and ICMT are being
developed that likely hold equal promise (Anderson et al., 2005; Dolence et al., 2000;
Manandhar et al., 2007; Porter et al., 2007; Schlitzer et al., 2001; Winter-Vann et al., 2005).
We previously screened a small-compound library for in vitro inhibitors of yeast Rce1p
(Manandhar et al., 2007). We identified nine compounds (compounds 1–9) with in vitro IC50
values in the low micromolar range. In the present study, our goal was to determine whether
these nine inhibitors can be used to modulate the in vivo activity of Rce1p. Through GFP–
Ras reporters and yeast of various deletion backgrounds, we demonstrate that the extent of
post-translational modification can significantly impact the intracellular targeting of CaaX
proteins and that these effects can be pharmacologically phenocopied. Our results support
the hypothesis that small-molecule CaaX protease inhibitors can be used to alter CaaX
protein localization and suggest that Rce1p inhibitors have potential as chemotherapeutics.
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Materials and methods
Yeast strains and media
The yeast strains used in this study are listed in Table 1. Plasmid-bearing versions of these
strains were generated according to published methods (Elble, 1992). Strains were routinely
grown at 30°C, with the exception of DF1 and plasmid transformants of this strain that were
grown at 25°C. Yeast were cultured using YEPD or synthetic complete drop-out glucosebased medium (e.g. SC–Ura and SC–Leu), as previously described (Michaelis and
Herskowitz, 1988). Experiments involving galactose-induced protein expression used
synthetic media lacking glucose and uracil (or leucine) but containing 2% galactose, 1%
glycerol and 1% ethanol (i.e. SGal–Ura and SGal–Leu).
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Plasmids
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The plasmids used in this study are listed in Table 2. pWS750 was constructed by
recombination-mediated plasmid construction. In brief, the BglII fragment encoding PGAL–
GFP–RAS2 from pWS270 was co-transformed into yeast with NotI-and XhoI-gapped
pRS315. The BglII fragment contains significant sequence homology at either end to
sequences of pRS315, which facilitates recombination events in vivo. Recombinant plasmid
clones were recovered from yeast surviving SC–Leu selection, amplified in E. coli DH5α,
and correct clones identified by restriction digest analysis. pWS751 was constructed by
replacing the RAS2 open reading frame (ORF) in pWS750 with that of YCK2 by
subcloning. A PCR fragment encoding YCK2 (amplified from pJB1) contained an XbaI site
immediately preceding the start codon and a NotI site immediately following the stop codon
of the YCK2 ORF; these sites flank the RAS2 ORF in pWS750. pWS808 was created by
recombination-mediated plasmid construction, such that the RAS1 ORF replaced the RAS2
ORF in pWS270 (Oldenburg et al., 1997). The RAS1 ORF was amplified by PCR (from
YEpRAS1), such that the product contained flanking sequences that were homologous to
sequences flanking the RAS2 ORF in pWS270. Yeast were co-transformed with the
appropriate PCR product and XbaI-linearized pWS270, plasmids were recovered from
clones surviving SC–Ura selection and the plasmids were evaluated by restriction digest
analysis. pWS881 was constructed in a similar manner to pWS750, except that pWS808 was
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used to generate the insert. The regions encoding the CaaX motifs in the above plasmids
were verified by DNA sequencing.
GFP–CaaX protein localization assay
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An inducible GFP–Ras2p reporter (pWS270 or pWS750) was used to determine the
localization of Ras2p in various genetic backgrounds and the ability of chemical agents to
disrupt Ras2p localization in wild-type cells (Manandhar et al., 2007). Reporters encoding
GFP–Ras1p, GFP–Yck2p and Sec63p–GFP were evaluated in a similar manner. In brief,
mid-log yeast cells containing the appropriate reporter were harvested, washed twice with
sterile H2O and incubated in SGal–Ura (or SGal–Leu) for approximately 6 h at 30°C to
induce expression of the inducible GFP reporters. Approximately 60–80% of cells had
strong GFP fluorescence with this protocol. Sec63p–GFP localization was examined under
both glucose and galactose conditions (SC–Ura and SGal–Ura, respectively). The expression
pattern of GFP reporters was visualized using a Zeiss Axioskop 2 Mot Plus microscope
equipped with fluorescence optics. Images were captured at × 100 magnification (plan
Apochromat objective, numerical aperture 1.4), using appropriate filters with an ORCA-AG
digital camera (Hamamatsu, Japan) and IPLab Spectrum software. For each experiment, at
least three cell fields were taken, from which representative images were selected. Images
for co-localization studies were false-colourized as appropriate, using Adobe Photoshop CS2
v. 9.0. Merged images were created by overlapping the false-colourized GFP image (50%
opacity) over that of the RFP image, using Adobe Photoshop CS2.
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For instances where compounds were evaluated, cells were pretreated with chemical agents
for 1 h at the appropriate induction temperature at their in vivo EC5 (concentration where
minimum growth inhibition is observed) or up to 50 μM in some instances. Following
pretreatment, the cells were washed with sterile distilled H2O and resuspended in
appropriate SGal-media as described above. EC5 concentrations were extrapolated from the
EC50 dataset using the equation ECF = (EC50)[F(100 — F)−1]1/H, where the percentage
value desired (F) was set to 5 and the Hill coefficient (H) was assumed to be 1 (Manandhar
et al., 2007; Motulsky, 2005). As indicated in the appropriate figure legends, the
pretreatment time or induction time varied. Where indicated, cells were treated before
microscopic evaluation with 1 μg/ml propidium iodide (Sigma) for 10 min (Marobbio et al.,
2003; Zhang, 2006).
Toxicity studies

Author Manuscript

The effects of exposure to small-molecule CaaX protease inhibitors on cell growth and
viability were determined using growth assays. To assess transient exposure, EG123
transformed with pWS270 was grown to mid-log phase (A600 = 0.5–1.0) in SC–Ura, the
culture split into 0.1 ml aliquots and the aliquots treated for 1 h with a range of inhibitor
concentrations (0–2 mM) in triplicate. Dilutions of the treated cultures were plated on YEPD
to evaluate the number of viable cells, as determined by colony counting after 48 h growth at
30°C. Colony counts were graphed vs. compound concentration, using GraphPad Prism 4.0
(four-parameter logistic equation) to determine EC50 toxicity values. The EC5
concentrations of compounds (calculated as described above) were re-evaluated by the plate
viability protocol after 6 h of galactose induction (7 h total exposure to compound) to
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validate the limited toxicity at these lower concentrations. The viabilities observed for EC5
treatment conditions are reported as a percentage relative to a DSMO-treated control. To
assess continuous exposure, a saturated yeast culture of EG123 transformed with pRS316
was highly diluted (1: 4000) into fresh SC–Ura and split into equal-volume aliquots (2 ml).
The individual aliquots were cultured on a rolling drum mixer in the presence of compounds
at the indicated concentrations until DMSO-treated cultures reached the density range A600
= 0.75–1.0 (approximately 22 h). A graph of A600 vs. concentration of inhibitors was
plotted, and EC50 toxicity values of the inhibitors were determined using GraphPad Prism
4.0, as described above.
Confocal laser scanning microscopy
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For experiments involving confocal microscopy, yeast were cultured and manipulated as
described above before being imaged, using a Zeiss LSM510 META confocal microscope
with a × 100 α-Plan Fluar 1.45 NA oil objective lens at a resolution of 0.04 μm per pixel.
GFP was excited with a 488 nm laser (0.3–4% intensity) and light emission captured
through a 505–530 nm BP filter. The laser intensity chosen yielded a linear fluorescence
response by the reporter (see Supporting information, Figure S1). The relative distribution of
GFP–Ras2p was determined with Zeiss LSM imaging software from a minimum of five
images. The values obtained were used to calculate the percentage of total fluorescence
associated with the plasma membrane, where delocalized fluorescence was defined as any
fluorescence 0.75 μm or more from the peak boundaries. The error in the associated bar
graphs represents the standard error of the mean (SEM) for each value.
Biochemical assessment of Rce1p activity in yeast treated with CaaX protease inhibitors
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A highly diluted culture of yeast over-expressing Rce1p-HA (SM3614 transformed with
pWS479) was grown for approximately 16 h at 30°C to mid-log (A600 = ∼1.0) in the
presence of DMSO or compounds 4 or 8 (at their EC10 and EC50 values, which are 6.8 and
61 μM for compound 4 and 10.8 and 97 μM for compound 8, respectively). The cells were
harvested by centrifugation (3000 × g for 5 min), washed once with distilled water and
frozen at −80°C. Thawed cells were used to prepare an ER-enriched membrane fraction, as
previously described (Manandhar et al., 2007; Porter et al., 2007). In brief, the cells were
converted to spheroplasts with Zymolyase 100T (Cape Cod Inc., East Falmouth, MA, USA),
lysed by mechanical agitation with silica beads (i.e. bead beating), and debris and unbroken
cells removed by low-speed centrifugation (500 × g for 10 min). Membranes were recovered
from the lysate by centrifugation (16 000 × g for 15 min), washed with lysis buffer (50 mM
Tris, pH 7.5, 0.2 M sorbitol, 1 mM EDTA, 0.02% NaN3) supplemented with protease
inhibitors (1 mM PMSF and 1 μg/ml each of chymostatin, leupeptin, pepstatin and
aprotinin), re-isolated by centrifugation and resuspended to 1 mg/ml in lysis buffer.
To assess the biochemical effects of compounds, Rce1p activity was analysed in duplicate,
using a fluorescence-based assay using equivalent amounts of membrane material (0.25
mg/ml) isolated as described above from each treatment condition (Manandhar et al., 2007).
The amount of activity observed was further normalized to the amount of Rce1p present in
each sample. Rce1p amounts were quantified using ImageJ (National Institutes of Health,
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Bethesda, MD, USA) from digital images of Rce1p immunoblots (Molecular Image FX
imaging system, Bio-Rad).

Results
GFP–Ras2p localization varies with its degree of post-translational modification

Author Manuscript

To qualitatively and quantitatively investigate the impact of post-translational modification
on Ras subcellular localization in yeast, we expressed GFP–Ras1p and GFP–Ras2p in yeast
having specific defects for each of the three steps associated with CaaX protein
modification. In yeast, as in other eukaryotic organisms, the Ras GTPases predominantly
decorate the cytosolic face of the plasma membrane (Figure 1A, B, WT). Quantification of
GFP–Ras2p fluorescence reveals that most (94%) of the total fluorescence in a wild-type
background is detected within 0.75 μm of the plasma membrane, as defined by readily
identifiable peak boundaries in cross-sectional fluorescence profiles of individual cells; this
type of analysis is the first quantitative measure of yeast Ras localization of which we are
aware. In an FTase-deficient strain (ram1Δ), a strong cytosolic localization pattern was
observed for the Ras reporters, and quantification of the GFP–Ras2p signal revealed that
only 19% of total fluorescence was near the plasma membrane. The pattern is consistent
with the role of isoprenoid lipids in mediating the membrane association of Ras proteins.
Importantly, the genetic background deficient for protein isoprenylation did not, in and of
itself, cause an alteration in plasma membrane composition that precluded affinity for lipidmodified proteins, as revealed by the normal localization pattern of GFP–Yck2p. Yck2p is a
palmitoylated and plasma membrane-localized protein whose maturation does not depend
upon the enzymes required for the modification of Ras and other CaaX proteins (Babu et al.,
2004).
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In the absence of CaaX protease activity, anywhere from one to several subcellular punctate
structures were observed for both of the Ras GTPases (rce1Δ ste24Δ; Figure 1A, B).
Quantification of GFP–Ras2p subcellular distribution revealed that <23% of the associated
fluorescence was near the plasma membrane. By comparison, GFP–Yck2p localization
appeared qualitatively normal. For GFP–Ras2p, the observed punctate pattern can be
contrasted to a more diffuse delocalized pattern observed in a CaaX protease-deficient yeast
strain of different lineage (Boyartchuk et al., 1997). To resolve the individual impact of each
CaaX protease, GFP–Ras1p and GFP–Ras2p were expressed in yeast lacking either Rce1p
(rce1Δ) or Ste24p (ste24Δ). Ste24p is not required for the proteolytic maturation of Ras
(Boyartchuk et al., 1997; Schmidt et al., 1998). As expected in the absence of Ste24p, GFP–
Ras localized predominantly to the plasma membrane, as determined by both qualitative and
quantitative measures (88% near plasma membrane for GFP–Ras2p). In the absence of
Rce1p, GFP–Ras was clearly delocalized (29% near plasma membrane for GFP–Ras2p), but
the pattern was more diffuse than seen in the absence of both CaaX proteases and was not
generally associated with punctate foci. The explanation for the differential pattern in the
rce1Δ by comparison to a complete CaaX protease-deficient background is unknown, but the
result suggests that Ste24p may play an indirect role in the localization of Ras2p
intermediates. Complementing these observations, we noted that the GFP–Ras2p pattern
reverted to the ste24Δ pattern (i.e. plasma membrane-associated) when yeast Rce1p was co-

Yeast. Author manuscript; available in PMC 2018 March 27.

Manandhar et al.

Page 7

Author Manuscript

expressed with the reporter in the CaaX protease-deficient background (rce1Δ ste24Δ;
Figure 1C); co-expression of yeast Ste24p led to a pattern similar to that seen in the rce1Δ
background.
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In cells lacking ICMT activity, the Ras GTPases were also delocalized (ste14-3; Figure 1A,
B). The diffuse distribution pattern was qualitatively similar to that observed for rce1Δ.
Quantification of GFP–Ras2p subcellular distribution in the ICMT-deficient background
revealed that 29% of the associated fluorescence was near the plasma membrane. Other
CaaX proteins are known to depend on ICMT for proper localization. For example, the
isoprenylated plant calmodulin CaM53 is targeted to the plasma membrane when
heterologously expressed in yeast, but is mistargeted to the endomembranes in the absence
of ICMT activity (Rodriguez-Concepcion et al., 2000). Mammalian Ras isoforms are
similarly mislocalized in the absence of ICMT activity (Bergo et al., 2000; Winter-Vann et
al., 2005).
Together, our results indicate that isoprenylation, CaaX proteolysis and ICMT activity are
critical for the proper plasma membrane localization of Ras1p and Ras2p but not the
palmitoylated protein Yck2p. Our qualitative observations indicate that defects in each of
these activities impart distinct biophysical properties to the Ras intermediate that are
reflected in distinct subcellular localization patterning. Our quantitative observations
indicate that each activity has approximately equal weight in helping promote the plasma
membrane localization. This latter observation suggests that inhibitors of the various steps of
the CaaX protein modification pathway are likely to have synergistic effects.
Certain CaaX protease inhibitors disrupt GFP–Ras2p localization

Author Manuscript

We previously identified nine compounds from the NCI Diversity Set Library that inhibit the
in vitro activity of Rce1p (Manandhar et al., 2007). In some instances, these compounds also
inhibited to varying degrees the in vitro activities of the Ste24p CaaX protease (compounds
3–9) and Ste14p ICMT (compounds 3–5, 8 and 9). Compounds 3–5, 8 and 9 also inhibited
the protease activity of trypsin. To investigate the in vivo properties of these compounds, we
examined whether any of the nine compounds were cytotoxic and subsequently whether any
could disrupt Ras2p localization inside yeast cells.
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The toxicity of these agents toward yeast was examined for both transient (1 hr) and
continuous exposures (Table 3). Transient exposures revealed that compounds 1, 2 and 5
were non-toxic up to 500 μM, the highest concentration evaluated. Compounds 3, 4 and 6–9
had varied toxicity, with compound 6 being the most toxic. A toxicity profile was also
obtained for continuous exposure. This analysis also revealed dose-dependent toxic effects
for many of the compounds. Compounds 6, 7 and 9 were most toxic under conditions of
continuous exposure. Compounds 1 and 2 had no detectable toxicity. Generally, compounds
with relatively lower EC50 values in the transient exposure study had relatively lower EC50
values in the continuous exposure study. Compound 7 was a notable exception, but it could
not be reliably evaluated as it did not yield a sigmoidal response in transient exposure
toxicity studies. The toxicity profiles and the reported observation that Rce1p is a nonessential protein suggest that some of the evaluated compounds (e.g. 6, 7 and 9) have offtargets that include essential processes. Interestingly, the tolerance of yeast to a particular
Yeast. Author manuscript; available in PMC 2018 March 27.
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compound did not correlate with observed in vitro specificity against CaaX-modifying
enzymes (Manandhar et al., 2007). For example, the somewhat selective in vitro Rce1p
inhibitor represented by compound 6 was cytotoxic, whereas the relatively non-specific
compound 5 was one of the least toxic compounds.
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We next investigated the ability of compounds to disrupt yeast Ras2p localization. In order
to minimize artifacts associated with cytotoxicity, we used concentrations where 95% or
greater viability was expected after transient exposure to a compound. At these minimally
toxic (EC5) concentrations, compounds 4 and 6–9 exerted GFP–Ras2p delocalization effects
consistent with loss of CaaX protease activity (i.e. punctate patterning), while others were
seemingly ineffective (Figure 2A, Table 3). Delocalization was observed despite the lack of
continuous exposure to compounds, suggesting that these compounds are cell-permeable and
tightly or otherwise irreversibly bind to their targets. None of the compounds induced the
diffuse GFP–Ras2p localization pattern observed in rce1Δ cells. We attribute this to the lack
of specificity of these compounds. Those that induced delocalization of GFP–Ras2p inhibit
both Rce1p and Ste24p in vitro (Manandhar et al., 2007). Thus, they are expected to
pharmacologically induce the pattern observed in a CaaX protease-deficient background
(rce1Δ ste24Δ). None of the compounds interfered with GFP–Yck2p localization, suggesting
that the compounds are not generally disrupting plasma membrane architecture or dynamics.
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To assess whether compounds 1, 2, 3 and 5 had any capability of inducing GFP–Ras2p
delocalization, we varied our protocol for compound concentration and exposure times, and
evaluated the effect of additives that aid in dispersal of compounds in solution. For example,
we examined the effect of continuous rather than transient exposure of cells to compounds,
using doses as high as 50 μM (1, 2 and 5) or 25 μM (3; higher doses were toxic). These
changes had no observable impact on GFP–Ras2p delocalization. Likewise, increasing the
transient dose (up to 100 μM) and duration (3 h) of compound treatment, alone or in
combination, also failed to induce an effect (data not shown). The presence of a non-toxic
amount of SDS (0.003%), however, did yield a delocalization phenotype in conjunction with
compound 3 at a concentration of 25 μM (Figure 2B). No such effect was observed with
compounds 1, 2 and 5, even when evaluated in the presence of other detergents (e.g. NP-40,
Tween 20, TX-100 or deoxycholate). Based on our combined observations, we conclude that
compounds 4 and 6–9 are highly cell-permeable, compound 3 is permeable when applied
with a dispersal agent, and compounds 1, 2 and 5 are either impermeable, unstable or
otherwise ineffective at interfering with proteolysis of the Ras2p CaaX protein in vivo.
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Compounds 4 and 8 were evaluated in more detail because they were among the least toxic
compounds that could induce a Ras delocalization phenotype. Treatment of wild-type cells
with these compounds induced quantifiable delocalization effects comparable to that
observed in the CaaX protease-deficient background (Figure 2C). By comparison with
DMSO-treated cells, where 93% of GFP–Ras2p was localized near the plasma membrane,
the reporter was localized 44% and 34% upon treatment with compounds 4 and 8,
respectively. Neither compound induced a delocalization phenotype to the extent observed
with complete loss of CaaX proteolytic activity (rce1Δ ste24Δ; 22% near the plasma
membrane).
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To support our contention that compounds are targeting Rce1p intracellularly, we predicted
that increasing the dosage of Rce1p would render inhibitors less effective. We tested this
prediction using compound 4 and plasmid-based expression of Rce1p, which increases
Rce1p production substantially over that observed when only the genomic copy of RCE1 is
available (Schmidt et al., 1998). With this approach, we observed that compound-induced
Ras2p delocalization in wild-type control cells (CEN) could be alleviated under conditions
of increased RCE1 gene dosage (CEN RCE1), suggesting that observed inhibitor effects are
indeed Rce1p-dependent (Figure 2D). The most parsimonious explanation for our
observations is that the Ras delocalizing agents described here are interfering with Rce1dependent CaaX proteolysis.
GFP–Ras2p delocalization is dependent on the duration of compound exposure
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In order to assess how quickly certain compounds could induce a Ras delocalization
phenotype, we carried out time-course experiments with compounds 4 and 8. Similar timedependent effects were seen with both compounds. As expected, extremely short
pretreatment times (1 min) did not delocalize the reporter from the plasma membrane
(Figure 3A). Punctate-patterning effects were observed with pretreatments as short as 20 and
40 min with compounds 4 and 8, respectively. The punctate patterns appeared without the
prior appearance of the diffuse intracellular pattern observed in rce1Δ cells. As discussed
above, we believe this to be due to the fact that compounds 4 and 8 inhibit both Rce1p and
Ste24p, in effect pharmacologically phenocopying a CaaX protease-deficient background.
We also determined that compounds 4 and 8 could not dislodge GFP–Ras2p, which had
been previously targeted to the plasma membrane, as judged by experiments in which
chemical agents were added to wild-type cells after induction of GFP–Ras2p expression
(Manandhar and Schmidt, unpublished observation).
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Additional time-course studies indicated that the compound-induced punctate patterning for
GFP–Ras2p was temporal. After prolonged (9 h) induction in galactose-medium or a
recovery in glucose-containing medium (3 h) after a standard 6 h induction, the plasma
membrane localization pattern was predominant in the population (Figure 3B). Several
possibilities could explain this observation. One is that there is synthesis of new, and thus
uninhibited, molecules of Rce1p during the induction period, which are free to act upon the
GFP–Ras2p intermediate accumulated at punctate sites. Alternatively, there could be
chemical breakdown or metabolism of the compound. Regardless of the reason for the
temporal effect, our observations suggest that punctate structures are dynamic in nature,
which we infer can only occur in live cells. To further confirm that toxicity was not a
contributing factor to our observations, we incubated compound treated yeast with the
nucleic acid dye propidium iodide, which stains dead yeast. Cells with GFP–Ras2p punctate
patterning went unstained, further supporting a lack of toxicity under the conditions tested,
whereas dead cells displaying whole cell patterning were stained by the dye (Figure 3C).
Yeast Rce1p activity is reduced in compound treated cells
The ability of certain Rce1p inhibitors to delocalize GFP–Ras2p in vivo, and the observation
that these effects are time-dependent, suggest that these particular compounds are cellpermeable. To directly assess whether intact yeast cells had reduced Rce1p expression
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and/or activity after exposure to these compounds, the Rce1p-enriched membrane fraction
was isolated from cells treated with or without these agents. For the purposes of this
experiment, Rce1p was overexpressed in the cells, which was necessary for measuring
Rce1p activity using our fluorescence-based biochemical assay. Membranes derived from
cells that were treated continuously with compounds 4 and 8 had the same level of Rce1p
expression as control membranes (Figure 4A) but had significantly reduced in vitro activity,
proportional to the amount of inhibitor used to treat the cells (Figure 4B). Interestingly,
membranes derived from cells treated with compound 8 had a readily observable yelloworange tint consistent with the colour of this compound; no such colour was associated with
membranes derived from cells treated with colourless compound 4 (Manandhar and
Schmidt, unpublished observation). Together, our observations are consistent with
compounds 4 and 8 being cell-permeable, and suggest that they inhibit the in vivo activity of
Rce1p by either directly modifying Rce1p or indirectly disrupting local membrane
architecture that is essential for Rce1p function.
Human Rce1p can promote the plasma membrane localization of GFP–Ras2p
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Several observations suggest that heterologously expressed human Rce1p can substitute for
yeast Rce1p in Ras2p maturation. First, H-Ras can substitute for the activity of yeast Ras2p,
implying that H-Ras is likely recognized by the native CaaX modification enzymes of yeast
(Kataoka et al., 1985). Second, human Rce1p is functional in yeast, as judged by its ability
to effectively process the farnesylated a-factor mating pheromone (Plummer et al., 2006).
Following up on these observations, we observe that human Rce1p can promote proper
plasma membrane localization of GFP–Ras2p in yeast devoid of the yeast CaaX proteases
(Figure 5A, DMSO-treated condition). We previously observed that, similar to yeast Rce1p,
the in vitro activity of human Rce1p is strongly inhibited by compounds 1–9 (Manandhar et
al., 2007). Therefore, we predicted that the GFP–Ras2p reporter could be used to monitor
the inhibitor sensitivity of human Rce1p in vivo. Indeed, compounds 3, 4, 6 and 9 induced
GFP–Ras2p delocalization in cells that heterologously express human Rce1p (Figure 5A).
Compound 3 induced delocalization only when SDS was present (Figure 5B). Compounds 7
and 8 were ineffective against human Rce1p when used at EC5 concentrations (11.1 and 5.1
μM, respectively) that induced a uniform delocalization phenotype in the context of yeast
Rce1p. However, a higher dose (25 μM) of compound 7 resulted in approximately 25% of
cells having a diffuse and occasional punctate GFP–Ras2p patterning (Figure 5B). Treatment
with higher doses was toxic to cells. Similar observations were made for compound 8. The
disparity between human and yeast Rce1p in response to compounds 7 and 8 may reflect
unequal expression levels of the enzymes in vivo. Yeast Rce1p is expressed from a single
genomic copy, whereas human Rce1p is expressed from a multi-copy plasmid and a strong
promoter. Target specificity differences are also possible. In fact, we have observed, both in
vitro and in a cell-based assay, that trypanosomal Rce1p is more sensitive to compound 7 as
compared to human Rce1p (Mokry et al., 2009). Together, our observations indicate that
GFP–Ras2p can be a useful reporter for human Rce1p activity and that the subcellular
distribution of GFP–Ras2p can be used as an indicator for determining the potency of
compounds in disrupting human Rce1p activity.
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Ras2p and the ER-specific marker Sec63p co-localize to subcellular foci in the absence of
CaaX proteolysis
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The fact that the yeast CaaX proteases are ER-localized is suggestive that non-proteolysed
CaaX proteins might be way-stationed at the ER. The localization pattern of GFP–Ras2p in
a CaaX protease-deficient background (rce1Δ ste24Δ), however, is not typical of ERlocalized proteins, such as Sec63p, Kar2p, Rce1p, Ste24p and Ste14p (Prinz et al., 2000;
Romano et al., 1998; Schmidt et al., 1998). To assess the pattern of the ER in our strain
background and under our assay conditions, we evaluated Sec63p–GFP, which is routinely
used as a marker protein for the yeast ER (Prinz et al., 2000). A typical ring-like ER
localization pattern was observed for the constitutively expressed reporter in genetic
backgrounds defective for the various steps associated with CaaX protein modification and
in compound treated wild-type cells (Figure 6A). The CaaX protease-deficient background
additionally displays occasional foci similar in appearance to those observed for GFP–Ras2p
in this background. Interestingly, foci became the predominant Sec63p-positive structure
when CaaX protease-deficient yeast were subjected to the galactose-induction protocol
typically used in conjunction with our GFP–Ras2p localization studies, suggesting an
unusual ER architecture under these conditions (Figure 6B).

Author Manuscript

The Sec63p–GFP foci apparent in CaaX protease-deficient yeast appeared similar enough to
those observed for GFP–Ras2p to suggest that they originated from the same source. We
investigated this issue through co-localization studies of GFP–Ras2p and Sec63p–RFP, using
CaaX protease-deficient yeast (rce1Δ ste24Δ) and wild-type yeast that had been treated with
and without compounds 4 and 8 (Figure 6C). In CaaX protease-deficient yeast, a significant
proportion of cells (63%, n = 51) had signal overlap between Sec63p–RFP and GFP–Ras2p.
In compound treated wild-type cells, GFP–Ras2p and Sec63-RFP localized to distinct nonoverlapping foci (compound 4, 9% overlap, n = 103; compound 8, 13% overlap, n = 32).
Therefore, it appears that GFP–Ras2p delocalizes predominantly to ER-derived structures in
the complete absence of the CaaX protease activity and to an undefined site in compound
treated cells. The lack of signal overlap between GFP–Ras2p and Sec63p–RFP upon
compound treatment may reflect incomplete inactivation of one or both of the CaaX
proteases in vivo, the temporal nature of delocalization, and/or the net effect of these
compounds on other targets, such as Ste14p, within the cell.

Discussion
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The most important observations of this study pertain to the impact of CaaX proteolysis on
Ras localization. To our knowledge, we have provided the first quantification of Ras
delocalization in the absence of the three steps in CaaX protein processing: isoprenylation,
proteolysis and carboxylmethylation. Our results demonstrate that Ras2p is significantly
delocalized from the plasma membrane in the absence of any of the three steps, despite the
observation that the subcellular distribution of our GTPase reporters varied somewhat
depending on the defective step. Together, these findings suggest that inhibitors of specific
steps associated with CaaX protein processing are likely to have synergistic effects when
combined.
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We have also demonstrated that small-molecule agents can chemically induce defects in
CaaX proteolysis that, at first glance, appear to pharmacologically phenocopy the Ras2p
delocalization effects seen in CaaX protease-deficient yeast. The most specific of the Rce1p
inhibitors, compounds 1 and 2, did not elicit a change in Ras2p localization despite
numerous attempts to improve the solubility and uptake of these compounds by yeast cells.
We previously reported that compounds 3–5, 8 and 9 have broad in vitro specificity,
including the ability to inhibit Ste24p and Ste14p (Manandhar et al., 2007). Several
compounds have also been identified as inhibitors of other enzymes, e.g. compounds 4 and 5
inhibit DNA topoisomerases (Bond et al., 2006; Stivers and Kwon, 2006). Nevertheless, the
compound induced Ras2p delocalization observed in vivo appears Rce1p-dependent, as
inferred from gene dosage experiments, and not the indirect result of disrupting the plasma
membrane architecture, as inferred from the normal subcellular distribution of Yck2p. The
in vivo targeting of Rce1p by these agents is further supported by the reduced biochemical
activity of Rce1p observed in membranes derived from compound treated yeast. Combined,
our observations and the fact that the activity of human Rce1p can be monitored using the
yeast GFP–Ras2p system suggest the possibility of using automated microscopy methods for
identifying cell-permeable human Rce1p inhibitors as part of drug discovery studies. As for
our current set of compounds, their ability to induce robust delocalization at low micromolar
concentrations is intriguing, but the associated toxicity of most clearly tempers the potential
of these agents as lead compounds in drug development trials. Whether these compounds
induce delocalization effects in, and are toxic to, mammalian cells remains to be determined.
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An intriguing observation made during the course of this study is that the classic ER marker
Sec63p partly localizes to subcellular foci in the absence of CaaX proteolytic activity under
standard culture conditions (i.e. glucose-containing media) (Figure 6A; rce1Δ ste24Δ).
These foci coexist with a more traditional ring-like ER pattern. A change in carbon source,
however, results in the foci becoming the prominent Sec63p-positive feature in the absence
of CaaX proteolytic activity and a transient feature in wild-type cells (Figure 6B). The foci
are not present in rce1Δ or ste24Δ single mutants grown in glucose (this study) or galactose
(Manandhar and Schmidt, unpublished observation). The ER is known to readily adapt its
structure to changing cellular needs (Federovitch et al., 2005). We propose a model in which
the classic ER pattern is dynamically remodelled in response to a nutritional change (i.e. the
replacement of glucose by galactose). This remodelling is short-circuited in the absence of
CaaX protease activity, resulting in foci. GFP–Ras2p is seen to co-localize to these ER-foci
in the absence of CaaX-proteolysis, where it is presumably anchored by the farnesyl moiety.
Despite co-localization between Sec63p and Ras2p in a CaaX protease-deficient
background, chemically induced Ras-containing foci do not contain significant amounts of
Sec63p, and thus may be derived from a separate ER subdomain or other organelle. The
reason for this discrepancy is unresolved, but could reflect redundancy in the ER
remodelling system, incomplete pharmacological inactivation of CaaX proteolytic activity,
or compounds acting promiscuously on other proteins (e.g. Ste14p) involved in Ras2p or
Sec63p trafficking (Dong et al., 2003; Wang and Deschenes, 2006). Further investigations
are needed to understand this phenomenon in the context of distinct nutritional stresses and
gene requirements.
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As mentioned above, we have occasionally observed Sec63p-positive foci in the wild-type
background upon a change in carbon source, but they are transient and relatively rare. The
presence of foci thus seems to be a normal part of ER remodelling. Since foci are not
persistent unless both CaaX proteases are absent, it can be reasoned that there may be CaaX
proteins involved in this remodelling event that either directly participate or regulate other
proteins in this process. A prime candidate is the chaperone Ydj1p, which is in part found at
the ER membrane, where it is involved in ER preprotein translocation and the turnover of
proteins, including those subject to ERAD (Caplan et al., 1992a; Mandal et al., 2008;
Trueblood et al., 2000; Youker et al., 2004). Defective post-translation processing of Ydj1p,
specifically lack of isoprenylation, disrupts the activation of certain Ydj1p-dependent
proteins, so it is possible that a lack of CaaX proteolysis has a similar effect (Flom et al.,
2008). We do not know, however, which if any Ydj1p client may be specifically involved in
ER remodelling. Unfortunately, the target specificities of the CaaX proteases have not been
fully resolved in any system, which complicates the identification of candidate CaaX
proteins involved in this proposed ER remodelling process. We envision several approaches
that may lead to the identification of CaaX proteins involved in ER remodelling (e.g. high
copy suppression studies) that could be utilized in future investigations of this phenomenon.
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Figure 1.
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The localization of GFP–Ras2p and GFP–Ras1p depends on proper post-translational
modification. (A) GFP–Ras2p, GFP–Ras1p and GFP–Yck2p reporters were inducibly
expressed in yeast that were wild-type (WT) or defective for the activity of the FTase
(ram1Δ), one or both of the CaaX proteases (rce1Δ, ste24Δ) or the ICMT (ste14-3). The
expression of the reporters, which were encoded behind the GAL1 promoter, was induced in
mid-log yeast by switching from glucose-to galactose-containing media. A field of cells and
an enlarged image are shown for GFP–Ras2p expressed in each background. An enlarged
image alone is shown for GFP–Ras1p and GFP–Yck2p that is representative of the field in
the indicated background. Plasmid-transformed strains of EG123 (WT), DF1 (ram1Δ),
SM1188 (ste14-3), SM3103 (ste24Δ), SM3613 (rce1Δ), and SM3614 (rce1Δ ste24Δ) were
used. With the exception of DF1, the plasmids used were pWS270 (GFP–RAS2), pWS808
(GFP–RAS1) and pJB1 (GFP–YCK2). For DF1, the plasmids used were pWS750 (GFP–
RAS2), pWS881 (GFP–RAS1) and pWS751 (GFP–YCK2). (B) Quantification of GFP–
Ras2p delocalization. Confocal laser scanning microscopy was used to determine crossYeast. Author manuscript; available in PMC 2018 March 27.
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sectional fluorescence profiles of WT and rce1Δ yeast (top and middle panels, respectively)
induced to express GFP–Ras2p. Data were collected using 1% of maximum laser strength at
488 nm. These profiles were used to calculate the amount of plasma membrane (PM)localized fluorescence, which is graphed along with the standard error of the mean (bottom
panel). The PM-localized fluorescence was defined as any fluorescence within 0.75 μm of
the peak boundaries. The strains used were the same as those described in (A). (C) Add-back
experiments confirm the dependence of GFP–Ras2p plasma membrane localization on
Rce1p. A CaaX protease-deficient strain (rce1Δ ste24Δ; yWS164) was assessed for GFP–
Ras2p localization as described in (A) after co-transformation with plasmids encoding
Rce1p or Ste24p. The plasmids used were pRS416 (CEN), pSM1107 (CEN STE24),
pSM1314 (CEN RCE1) and pWS750 (GFP–RAS2)

Author Manuscript
Author Manuscript
Author Manuscript
Yeast. Author manuscript; available in PMC 2018 March 27.

Manandhar et al.

Page 19

Author Manuscript
Author Manuscript
Author Manuscript
Figure 2.
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GFP–Ras2p can be delocalized by chemical agents. GFP–Ras2p and GFP–Yck2p were
inducibly expressed in wild-type yeast, as described in Figure 1, after a transient 1 h
pretreatment with the indicated compound. The compounds were used at EC5
concentrations, as calculated from transient exposure toxicity studies (see Table 3). (B)
Compound 3 has latent GFP–Ras2p delocalization activity. GFP–Ras2p was inducibly
expressed in wild-type yeast after 1 h pretreatment with 25 μM of the indicated compounds
in the presence of 0.003% SDS. (C) GFP–Ras2p was inducibly expressed in wild-type yeast
treated with compounds 4 or 8 at EC5 concentrations. Cross-sectional fluorescence profiles
were collected and used to calculate the relative amount of plasma membrane-localized
fluorescence, which is graphed along with the standard error of the mean, as described in
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Figure 1. (D) Increased dosage of RCE1 restores normal GFP–Ras2p localization in
compound treated cells. Wild-type yeast cells carrying either an empty plasmid or low-copy
RCE1 plasmid were treated with DMSO or 25 μM compound 4, followed by induction of
GFP–Ras2p expression. The strain used was EG123 (WT) and the plasmids were pRS416
(CEN) and pSM1314 (CEN RCE1)
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Figure 3.
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Time-course studies of chemically induced GFP–Ras2p delocalization. (A) Compoundinduced Ras delocalization is dependent on pretreatment time. GFP–Ras2p was inducibly
expressed in wild-type yeast (EG123), as described in Figure 2, after pretreatment with the
EC5 concentration of compounds 4 or 8 for the indicated times. (B) Compound-induced
delocalization is transient. Wild-type yeast (EG123) cells were compound treated and
induced as described in Figure 2 (6 h), then a portion of cells was incubated in induction
medium for an additional 3 h (9 h) or switched to glucose-containing medium and incubated
for an additional 3 h (Gal → Glu). (C) Compound-induced delocalization of GFP–Ras2p
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occurs in living cells. Wild-type yeast cells were pretreated with compound 8 and induced to
express GFP–Ras2p, as described in Figure 2. After a 6 h induction period, the cells were
stained with the nucleic acid dye propidium iodide (PI). The GFP and PI fluorescence
signals observed for the same field of cells are shown. Within the cluster of cells shown,
there are several live cells and one dead cell
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Figure 4.
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Effect of in vivo compound exposure on expression and in vitro biochemical activity of
yeast Rce1p. (A) In vivo compound exposure does not significantly alter Rce1p expression
levels. Membranes were prepared from yeast over-expressing Rce1p that had been treated
with DMSO or compounds 4 or 8 at their EC50 (61 and 97 μM, respectively) and EC10 (6.8
and 10.8 μM, respectively) concentrations; both treatment conditions yielded similar results,
so only those associated with EC50 treatment are shown. Each treatment was performed in
triplicate and independent membrane fractions recovered. An equal amount of total protein
from each sample was analysed by SDS–PAGE and immunoblot, using an anti-HA antibody.
(B) In vivo compound exposure reduces Rce1p activity in a dose-dependent manner. The
membrane fractions described in (A), including those from the repeat experiment, were
directly evaluated in duplicate for CaaX protease activity, using a fluorescent-based in vitro
assay, yielding six (EC50) or 12 data points (EC10) for each individual treatment condition.
These values were averaged, normalized to Rce1p expression levels, and are reported
relative to the activity of the DMSO-treated condition. Statistical analysis was performed
using Student’s t-test, using the DMSO-treated condition as the reference; p < 0.003. The
yeast used for Rce1p over-expression was strain SM3614, and the plasmid encoding Rce1p
was pWS479

Author Manuscript
Yeast. Author manuscript; available in PMC 2018 March 27.

Manandhar et al.

Page 24

Author Manuscript
Author Manuscript
Author Manuscript

Figure 5.

GFP–Ras2p is an effective reporter for human Rce1p activity. GFP–Ras2p was inducibly
expressed in yeast expressing human Rce1p as the sole source of CaaX proteolytic activity.
Cells were pretreated for 1 h with or without the indicated compounds prior to induction as
described in Figure 2. The strain used was yWS164 (rce1Δ ste24Δ) co-transformed with
pWS335 (HsRce1) and pWS750 (GFP–RAS2). The concentrations used were EC5 (A) or 25
μM (B)
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Figure 6.
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The localization pattern of the ER-marker Sec63p–GFP depends on genetic background and
nutritional status. (A) The distribution of Sec63p–GFP in yeast defective for the various
steps associated with CaaX processing and in compound treated wild-type cells is relatively
normal for cultures grown in glucose. The strains used were pJK59 transformants of the
backgrounds described in Figure 1, with the exception of ram1Δ, which was not evaluated.
(B) The distribution of Sec63p–GFP in wild-type (EG123) and CaaX protease-deficient
(SM3614) yeast varies under conditions mimicking the protocol associated with GFP–Ras2p
induction. Yeast were switched to galactose-containing media and images captured at the
indicated times. (C) Co-localization of GFP–Ras2p (pWS750) and Sec63p–RFP (pSM1960)
occurs under inducing conditions (galactose) only in the absence of CaaX proteolytic
activity. The distribution of the indicated reporters in wild-type (EG123), CaaX proteasedeficient (yWS164), and compound treated wild-type yeast was evaluated as described in
Figure 2. Digital images were captured using either a fluorescein (left panel) or a rhodamine
filter (middle panel) to capture GFP and RFP fluorescence, respectively. Merged images are
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shown in the right panel. Where indicated, yeast were treated with compound 4 or 8 (each at
25 μM)
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Strains used in this study
Strain

Genotype

Reference

DF1

MATa trp1 leu2 ura3 his4 can1 ram1::URA3

(He et al., 1991)

EG123

MATa trp1 leu2 ura3 his4 can1

ATCC No. 204 278

SM3103

MATa trp1 leu2 ura3 his4 can1 ste24::LEU2

(Fujimura-Kamada et al., 1997)

SM3613

MATa trp1 leu2 ura3 his4 can1 rce1::TRP1

(Tam et al., 1998)

SM3614

MATa trp1 leu2 ura3 his4 can1 rce1::TRP1 ste24::LEU2

(Tam et al., 1998)

SM1188

MATa trp1 leu2 ura3 his4 can1 ste14-3::TRP1

(Hrycyna et al., 1991)

yWS164

MATa trp1 leu2 ura3 his4 can1 rce1::TRP1 ste24::KANR mfa1-Δ1 mfa2-Δ1

(Cadiñanos et al., 2003)
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Plasmids used in this study
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Plasmid

Genotype

Reference

pJB1

CEN URA3 PGAL-GFP-YCK2

(Robinson et al., 1999)

pJK59

CEN URA3 SEC63-GFP

(Prinz et al., 2000)

pRS315

CEN LEU2

(Sikorski and Hieter, 1989)

pRS316

CEN URA3

(Sikorski and Hieter, 1989)

pRS416

CEN URA3

(Sikorski and Hieter, 1989)

pSM1107

CEN URA3 HAn::STE24

(Fujimura-Kamada et al., 1997)

pSM1314

CEN URA3 RCE1::HAc

(Schmidt et al., 1998)

pSM1960

2 μ URA3 SEC63-RFP

Gift of S. Michaelis

pWS270

CEN URA3 PGAL-GFP-RAS2

(Manandhar et al., 2007)

pWS335

2 μ URA3 PPGK-HIS::HA::HsRce1Δ22

(Plummer et al., 2006)

pWS479

2 μ URA3 PPGK-RCE1::HAc

(Plummer et al., 2006)

pWS750

CEN LEU2 PGAL-GFP-RAS2

This study

pWS751

CEN LEU2 PGAL-GFP-YCK2

This study

pWS808

CEN URA3 PGAL-GFP-RAS1

This study

pWS881

CEN LEU2 PGAL-GFP-RAS1

This study

YEpRAS1

2 μ LEU2 RAS1

(Kataoka et al., 1984)
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1.8

5.1

11.1

93 ± 6

104 ± 14

100 ± 8

92 ± 6

108 ± 2

110 ± 0

129 ± 6

115 ± 2

109 ± 4

Growth at EC5 (%)

Yes

Yes

Yes

Yes

No

Yes

Yes

No

No

Delocalization observedc

0.08

4.34

0.07

0.07

60.63

14.00

7.90

>500

>500

EC50 (μM)

Continuous exposure

Cell viability did not display a sigmoidal response to this compound.

d

A positive score for delocalization after transient compound treatment required at least 50% of cells in the viewing area to have a discernible delocalization phenotype. Minimum treatment concentrations
exerting an effect were EC5 (compounds 4, 6–9) or 25 μM (compound 3; also required 0.003% SDS); other compounds (compounds 1, 2 and 5) had no effect at the highest concentration evaluated (50 μM).

Extrapolated from transient exposure EC50 dataset, assuming a Hill coefficient of 1; see Materials and methods for details.

b

c

97

7d

26.3

3.2

3.7

26.3

26.3

EC5 (μM)b

As previously reported (Manandhar et al., 2007).
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